Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells

Liu, Yu; Zhao, Yan; Han, Chongxu; Ren, Chuan-li

doi:10.1155/2022/2402567

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TP53 mutation is often used as a biomarker for diagnosis and prognosis, and as a potential therapeutic target for GC. CDKN1A (p21), cyclin‐dependent kinase inhibitor 1A, is a mediator of p53 tumour suppressor activity based on growth arrest, differentiation and senescence functions 52 ; CDK4 is a member of the Ser/Thr protein kinase family, and its partner gene CDK6, is the core driver of the cell cycle 53 and plays a crucial role in the occurrence and development of various malignant tumours including GC; p21 can promote tumorigenesis by promoting the assembly of CDK4/CDK6 complex 54 . CDH1 (E‐cadherin) and its related signalling pathways play important physiological roles in maintaining cell adhesion, structure, motility and cell homeostasis 55 ; CDH1 mutation is also associated with GC; and both dysregulation and mutation of the CDH1 gene can increase the proliferation, invasion and/or metastasis of GC cells and promote the occurrence and development of GC 56,57 .…”

Section: Discussionmentioning

confidence: 99%

Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology

Liu,

Huang,

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Ellagic acid (EA) is a natural polyphenolic compound. Recent studies have shown that EA has potential anticancer properties against gastric cancer (GC). This study aims to reveal the potential targets and mechanisms of EA against GC. This study adopted methods of bioinformatics analysis and network pharmacology, including the weighted gene co‐expression network analysis (WGCNA), construction of protein–protein interaction (PPI) network, receiver operating characteristic (ROC) and Kaplan–Meier (KM) survival curve analysis, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, molecular docking and molecular dynamics simulations (MDS). A total of 540 EA targets were obtained. Through WGCNA, we obtained a total of 2914 GC clinical module genes, combined with the disease database for screening, a total of 606 GC‐related targets and 79 intersection targets of EA and GC were obtained by constructing Venn diagram. PPI network was constructed to identify 14 core candidate targets; TP53, JUN, CASP3, HSP90AA1, VEGFA, HRAS, CDH1, MAPK3, CDKN1A, SRC, CYCS, BCL2L1 and CDK4 were identified as the key targets of EA regulation of GC by ROC and KM curve analysis. The enrichment analysis of GO and KEGG pathways of key targets was performed, and they were mainly enriched in p53 signalling pathway, PI3K‐Akt signalling pathway. The results of molecular docking and MDS showed that EA could effectively bind to 13 key targets to form stable protein–ligand complexes. This study revealed the key targets and molecular mechanisms of EA against GC and provided a theoretical basis for further study of the pharmacological mechanism of EA against GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology

Liu,

Huang,

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, this is possibly the first report identifying these five miRNAs as differentially expressed and regulating different host genes such as CDK6, CD276, CDC42, DNMT3A, CXXC6 etc. CDK6 is known to phosphorylate and regulate the expression of tumor suppressor proteins, and its altered expression has been observed in prostate cancer (Chen et al, 2022), stomach cancer (Liu et al, 2022), and coronary artery disease (Witten et al, 2022). CD276 belongs to the immunoglobulin superfamily of proteins and participate in the regulation of T-cell-mediated immune response (Liu et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic analyses of differentially expressed genes, micro RNAs and long-non-coding RNAs in severe, symptomatic and asymptomatic malaria infection

Oboh

Morenikeji

Ojurongbe

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Malaria transmission and endemicity in Africa remains hugely disproportionate compared to the rest of the world. The complex life cycle of P. falciparum (Pf) between the vertebrate human host and the anopheline vector results in differential expression of genes within and between hosts. An in-depth understanding of Pf interaction with various human genes through regulatory elements will pave way for identification of additional tool in the arsenal for malaria control. Therefore, the regulatory elements (REs) involved in the over- or under-expression of various host immune genes hold a key to alternative control measures that can be applied for prompt diagnosis and treatment. Methods: We carried out an RNAseq analysis to identify differentially expressed genes and network analysis of non-coding RNAs and target genes associated with immune response in individuals with different clinical outcomes. Raw RNAseq datasets, retrieved for analyses include individuals with severe (Gambia - 20), symptomatic (Burkina Faso - 15), asymptomatic (Mali - 16) malaria as well as uninfected controls (Tanzania - 20; Mali - 36). Results: Of the total 107 datasets retrieved, we identified 5534 differentially expressed genes (DEGs) among disease and control groups. A peculiar pattern of DEGs was observed, with individuals presenting with severe/symptomatic malaria having the highest and most diverse upregulated genes, while a reverse phenomenon was recorded among the asymptomatic and uninfected individuals. In addition, we identified 141 differentially expressed (DE) miRNA, of which 78 and 63 were upregulated and downregulated respectively. Interactome analysis revealed a moderate interaction between DEGs and miRNAs. Of all identified miRNA, five were unique (hsa-mir-32, hsa-mir-25, hsa-mir-221, hsa-mir-29 and hsa-mir-148) because of their connectivity to several genes, including hsa-mir-221 connected to 16 genes. Six-hundred and eight DE lncRNA were identified, including SLC7A11, LINC01524 among the upregulated ones. Conclusion: Our study provides important insights into host immune genes undergoing differential expression under different malaria conditions. It also identified unique miRNAs and lncRNAs that modify and/or regulate the expression of various immune genes. These regulatory elements, we surmise have the potential to serve a diagnostic purpose in discriminating between individuals with severe/symptomatic malaria and those with asymptomatic infection or uninfected.

show abstract

“…CDK6 expression has been shown to be elevated and associated with poor prognosis in gastric cancer. The CDK4/6 inhibitor PD-0332991 promotes the apoptosis and senescence of gastric cancer cells and inhibits the migration and invasion of gastric cancer cells ( Liu et al, 2022 ). In the NCT03446157 study, the CDK4/6 inhibitor palbociclib was used in combination with the CD73 inhibitor AB680, showing potential for antitumor efficacy in animal models of CRC ( He et al, 2018 ; Noh et al, 2022 ).…”

Section: Mechanism Of Anti-senescence Therapy In Gi Cancermentioning

confidence: 99%

A strategy for the treatment of gastrointestinal cancer: Targeting tumor senescent cells

Liu

Zhang²,

Ni³

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Gastrointestinal (GI) cancer includes a variety of cancers with high incidence that seriously threaten the lives of people worldwide. Although treatment strategies continue to improve, patient benefits are still very limited, and the ongoing search for new treatment strategies remains a priority. Cell senescence is closely related to the occurrence and development of tumors. For GI cancer, cell senescence may not only promote cancer but also bring new opportunities for treatment. Combined with relevant studies, we review the dual role of cell senescence in GI cancer, including the mechanism of inducing cell senescence, biomarkers of senescent cells, and potential of targeted senescence therapy for GI cancer.

show abstract

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells

Cited by 5 publications

References 17 publications

Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology

Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology

Transcriptomic analyses of differentially expressed genes, micro RNAs and long-non-coding RNAs in severe, symptomatic and asymptomatic malaria infection

A strategy for the treatment of gastrointestinal cancer: Targeting tumor senescent cells

Contact Info

Product

Resources

About